The College of American Pathologists (CAP) President Donald Karcher, MD, FCAP, will provide testimony to the House Energy and Commerce Subcommittee on Health during a hearing entitled “Evaluating Approaches to Diagnostic Test Regulation and the Impact of FDA’s Proposed Rule “ on March 21.
The CAP greatly appreciates the leadership of the Energy and Commerce Committee and its members for prioritizing this issue and holding a congressional hearing to further explore the oversight of laboratory-developed tests. Through the years, the CAP has advocated for an oversight approach that ensures patient safety and access to quality testing, mitigates regulatory burden on laboratories, and allows for the continued innovation of new tests. For more information on the CAP’s position on this issue, read Dr. Karcher’s recent column in CAP TODAY and the CAP’s December 4, 2023 letter to the Food and Drug Administration regarding the agency’s proposed LDT oversight regulation.
For more information about the hearing, please visit the Energy and Commerce Committee press release.